Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02112656 · ClinicalTrials.gov registry record · Phase 3

Study of ThermoDox With Standardized Radiofrequency Ablation (RFA) for Treatment of Hepatocellular Carcinoma (HCC)

A Phase 3 study of Hepatocellular Carcinoma, sponsored by Imunon.

Completed
Registry status
Phase 3
Development phase
554
Enrollment target
20
Study locations

NCT02112656 is a Phase 3 study of Hepatocellular Carcinoma that has completed, run by Imunon. The registered enrollment target is 554 participants, above the 254-participant average among 145 other Hepatocellular Carcinoma trials with a reported enrollment target (118% higher). The trial reports 20 study locations across 5 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02112656, a Phase 3 study of Hepatocellular Carcinoma, has completed, sponsored by Imunon.

COMPLETED
Registry status
Phase 3
Development phase
554 participants
Enrollment target
20
Study locations

Study Summary

The purpose of this study is to determine whether ThermoDox, a thermally sensitive liposomal doxorubicin, is effective in the treatment of non-resectable hepatocellular carcinoma when used in conjunction with standardized radiofrequency ablation (sRFA).

Conditions Studied

Hepatocellular Carcinoma

Interventions

  • DRUG ThermoDox
  • DRUG Dummy infusion

Study Locations (20)

Other

  • Peking University First Hospital - Beijing
  • Beijing Cancer Hospital, School of Oncology, Peking - Beijing
  • 302 Military Hospital of China - Beijing
  • Beijing Hospital of the Ministry of Health - Beijing
  • Chinese PLA General Hospital - Beijing
  • West China Hospital of Sichuan University - Chengdu
  • The Second Hospital of Dalian Medical University - Dalian
  • Guangdong General Hospital - Guangdong
  • Hunan Cancer Hospital - Hunan
  • The First Hospital of Jilin University - Jilin
  • Zhongshan Hospital, Fudan University - Shanghai
  • The Sixth People's Hospital of Shenyang - Shenyang
  • The 3rd Hospital of Tianjing - Tianjin
  • The First Hospital of Zhejiang - Zhejiang
  • Zhejiang Cancer Hospital - Zhejiang
  • Institut für Diagnostische und Radiologische Therapie del Uniklinik Frankfurt - Frankfurt

California

  • UCLA Department of Medicine - Los Angeles

Ontario

  • Toronto General Hospital - Toronto

Fujian

  • Mengchao Hepatobiliary Hospital of Fujian Medicatl University - Fuzhou

Shaanxi

  • Xijing Hospital - Xi'an

Trial Details

FieldValue
Enrollment Target 554 participants
Start Date 2014-06
Est. Completion 2020-04-27
Phase Phase 3

Sponsor

Imunon

11 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT02112656

The ClinicalTrials.gov registry entry for NCT02112656 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 554 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 254-participant average among 145 other Hepatocellular Carcinoma trials with a reported enrollment target (118% higher). The listed sponsor is Imunon, which has 11 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Hepatocellular Carcinoma appearing as the primary indexed condition, and to 2 interventions - of which ThermoDox is the first listed.

NCT02112656 reports 20 study locations spanning 5 distinct geographic areas - top geographies include Other, California, Ontario.

Frequently Asked Questions

What is clinical trial NCT02112656 about?

NCT02112656 is a clinical study titled "Study of ThermoDox With Standardized Radiofrequency Ablation (RFA) for Treatment of Hepatocellular Carcinoma (HCC)". The purpose of this study is to determine whether ThermoDox, a thermally sensitive liposomal doxorubicin, is effective in the treatment of non-resectable hepatocellular carcinoma when used in conjunction with standardized radiofrequency ablation (sRFA).

What is the current status of trial NCT02112656?

This trial is currently completed. It is a Phase 3 study. The enrollment target is 554 participants. The study started on 2014-06. Estimated completion is 2020-04-27.

What conditions does trial NCT02112656 study?

This clinical trial studies the following conditions: Hepatocellular Carcinoma.

What interventions are being tested in trial NCT02112656?

The interventions under investigation include: ThermoDox (DRUG), Dummy infusion (DRUG).

Who is sponsoring clinical trial NCT02112656?

This trial is sponsored by Imunon, which has 11 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02112656 being conducted?

This trial has 20 study locations across California, Ontario, Fujian, Shaanxi. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Hepatocellular Carcinoma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Hepatocellular Carcinoma

All registered trials for this condition

California

All trials with a study site in California

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.